

Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes

Jérémy Seurat, Thu Thuy Nguyen and France Mentré

Université de Paris, IAME, INSERM, F-75018 Paris, France

Journées du GDR « Statistiques et santé »
10-11 octobre 2019

Design in mixed effect models

- Nonlinear mixed effect models (NLMEMs)
 - Estimation of population parameters
 - Fixed effects (mean, covariate effects)
 - Variance of random effects (inter-individual variability)
 - Appropriate for exploiting the richness of longitudinal data
 - For both continuous and discrete data

- Problem beforehand: choice of population design
 - To obtain precise estimates / adequate power (Wald test)
 - Number of individuals ? Number and allocation of sampling times ? Dosing regimen ? ...

Design and Fisher Information Matrix

- Design evaluation and optimization
 - Clinical trial simulation (CTS): time consuming
 - Fisher Information Matrix (FIM)
 - Inverse of FIM: lower bound of the variance-covariance matrix of any unbiased estimated parameters (Cramér-Rao)
- Computation of FIM
 - First order (FO) linearization of the model around the expectation of random effects¹
 - Efficient in general but presents limitations with complex models and discrete data
 - New approaches for both continuous and discrete models
 - Monte Carlo/Hamiltonian Monte Carlo (MC/HMC)²
 - Monte Carlo/Adaptive Gaussian Quadrature (MC/AGQ)³

1: Mentré *et al.*, Biometrika, 1997

2: Riviere *et al.*, Biostatistics, 2016

3: Ueckert *et al.*, Comput Stat Data Anal, 2017

Model uncertainty in design

- Design evaluation and optimization require knowledge on model
- Local planification: given one model and its parameter values
- Alternative: Robust designs accounting for model uncertainty

Objectives

- To develop a FIM-based strategy to
 - Account for **model uncertainty** (robust designs)
 - Find a balance between the power of the Wald test and the precision of all the estimated parameters
- To illustrate this strategy with repeated binary data
- To evaluate this strategy by clinical trial simulations (CTS)

NLMEMs for discrete outcomes

- For a given model m , where the conditional probability for observation y_{ij} of individual i at sample j ($j = 1, \dots, n_i$) is:

$$p(y_{ij}|b_i) = h_m(y_{ij}, \xi_i, g(\mu_m, b_i, z_i, \beta_m)),$$

with

h_m : structural model for m

ξ_i : elementary design for individual i

μ_m : vector of fixed effects for m

b_i : vector of random effects for individual i , $b_i \sim N(0, \Omega_m)$

z_i : vector of covariates

β_m : vector of covariate effects for m

ψ_m : population parameters $\{\mu_m, \beta_m, \Omega_m\}$

Fisher Information Matrix

- FIM \mathcal{M} evaluation based on *Monte Carlo/Hamiltonian Monte Carlo* (R package *MIXFIM*¹)

$$\mathcal{M}(\psi, \xi) = E_y \left(\frac{\partial \log L(y; \psi)}{\partial \psi} \frac{\partial \log L(y; \psi)^T}{\partial \psi} \right)$$

ψ : population parameters
 ξ : elementary design
 y : observations
 L : likelihood
 Ξ : population design

 - Elementary FIM

$$\mathcal{M}(\psi, \Xi) = N \times \mathcal{M}(\psi, \xi),$$

with identical elementary design ξ in all N individuals
 - Population FIM
- Standard errors of parameters predicted from FIM
 - Power of the Wald test
- Design optimization: criteria based on FIM

1: Riviere MK. et al., Biostatistics, 2016

Optimality criteria

Parameters of interest	Given model m	
All the parameters ψ_m	D-optimality ¹ $\Phi_{D,m}(\Xi) = \text{Det}(\mathcal{M}(\psi_m, \Xi))^{1/P_m}$	

Ξ : population design

ψ_m : vector of parameters of the model m (of size P_m), including parameters of interest $\psi_{S,m}$ (of size S_m)

and other parameters $\psi_{T,m}$, \mathcal{M}_T : FIM on $\psi_{T,m}$

α_m : interest in the precision of estimation for $\psi_{S,m}$, $0 \leq \alpha_m \leq 1$

$$\sum_{m=1}^M w_m = 1$$



1: Atkinson AC. et al., Optimum experimental designs, 2007

2: Atkinson AC. et al., J Stat Plan inference, 2008

3: Nguyen TT. et al., Pharm Stat, 2016

Candidate Models & Parameters

- Repeated binary data, 2 balanced groups : Control \
- Logistic models describing probability p of response y over times



$\theta_p = \mu_p + b_p$ where $b_p \sim N(0, \omega_p^2)$, β : effect size of the treatment on θ_2

	ψ_1	ψ_2	ψ_3	ψ_4
μ_1	-2	-2	-2	-2
μ_2	0.09	0.42	0.0075	0.02015
μ_3	-	-	-	1/3
β	5	5	5	5
ω_1	0.7	0.7	0.7	0.7
ω_2	0.17	0.79	0.014	0.0379

Design optimisation accounting for model uncertainty

- Based on CDD_S-criterion Φ_{CDD_S}
 - Parameter of interest: β
 - Total model uncertainty: $w_1 = w_2 = w_3 = w_4 = 0.25$

- Constraints

Measures / individual	n = 4 (among times from 0 to 12 months)
Measuring times $\xi=(t_1, t_2, t_3, t_4)$	$t_1 = 0, t_4 = 12$ months (fixed) t_2, t_3 optimized among 11 times from 1 to 11



- Combinatorial optimisation: 55 possible designs

DD_s-efficiencies for each model


$$E_{DD_s, m}(\xi) = \frac{\Phi_{DD_s, m}(\xi)}{\Phi_{DD_s, m}(\xi_{DD_s, m})}$$

■ DD_s-Optimal design ($\xi_{DD_s, m}$)

M1




$\xi_{DD_s, 1} = (0, 2, 11, 12)$




CDD_s-efficiencies

$$E_{\text{CDD}_s}(\xi) = \frac{\Phi_{\text{CDD}_s}(\xi)}{\Phi_{\text{CDD}_s}(\xi_{\text{CDD}_s})}$$



$\xi_{\text{CDD}_s} = (0, 4, 11, 12)$



Predicted performances of different designs







D-efficiencies

$$E_{D,m}(\xi) = \frac{\Phi_{D,m}(\xi)}{\Phi_{D,m}(\xi_{D,m})}$$

Model \ Design		M1 Linear	M2 Loglinear	M3 Quadratic	M4 Exponential
Equi-spaced design	$\xi_{ES}=(0,4,8,12)$	0.908	0.926	0.975	0.869
DD _S -optimal design for M1	$\xi_{D,1}=\xi_{DS,1}=\xi_{DDs,1}=(0,2,11,12)$	1	0.898	0.812	0.706
	$\xi_{D,2}=(0,1,8,12)$	0.932	1	0.875	0.787
	$\xi_{DS,2}=\xi_{DDs,2}=(0,1,11,12)$	0.932	0.998	0.796	0.685
	$\xi_{D,3}=(0,4,5,12)$	0.916	0.839	1	0.646
	$\xi_{DS,3}=\xi_{DDs,3}=(0,5,11,12)$	0.860	0.805	0.994	0.958
	$\xi_{D,4}=(0,6,11,12)$	0.829	0.802	0.960	1
	$\xi_{DS,4}=(0,10,11,12)$	0.754	0.770	0.786	0.775
	$\xi_{DDs,4}=(0,9,11,12)$	0.771	0.777	0.813	0.864
	$\xi_{CD}=(0,5,11,12)$	0.860	0.805	0.994	0.958
Robust design	$\xi_{CDs}=\xi_{CDDs}=(0,4,11,12)$	0.910	0.828	0.977	0.882

Predicted performances of different designs

Power


 $\xi_{\text{CDDs}} = (0, 4, 11, 12)$

 $\xi_{\text{DDs},1} = (0, 2, 11, 12)$

 $\xi_{\text{ES}} = (0, 4, 8, 12)$


NSN to reach
 $\pi_{\text{average}} = 0.9$

274


320

358

$$\text{Average power: } \pi_{\text{average}}(\Xi) = \sum_{m=1}^M w_m \times \pi_m(\Xi)$$

Clinical trial simulations (CTS)

- 500 simulated datasets under each candidate model and 3 different designs: ξ_{CDDs} , $\xi_{\text{DDs},1}$, ξ_{ES}
- Estimations of the parameters under the simulated model using SAEM algorithm (Monolix 2016 R1)




- Comparison of the performances of the robust design ξ_{CDDs} with $\xi_{\text{DDs},1}$ and ξ_{ES}
- Adequation between FIM predictions and CTS results

Relative estimation errors and bias


REE: Relative estimation error, in %

RB: Relative bias, in %


$\xi_{ES} = (0, 4, 8, 12)$



$\xi_{DDs,1} = (0, 2, 11, 12)$




$\xi_{CDDs} = (0, 4, 11, 12)$



Adequacy FIM predictions vs. CTS estimations (ξ_{CDDs} , N=274)

- Parameters estimation precision



- Type 1 error & Power of the Wald test on β


Under H_0				
Nominal type I error	0.05 [0.033,0.073]			
Observed type I error	0.048	0.060	0.068	0.036
Under H_1				
FIM predicted power	0.967 [0.949,0.982]	0.889 [0.859,0.916]	0.973 [0.959,0.986]	0.769 [0.731,0.792]
Observed power	0.988	0.988	0.996	0.860

Discussion

- Method to design longitudinal studies with binary outcome accounting for model uncertainty
- Compromise between overall parameter precision and power of the Wald test
- Relevance of the approach evaluated by simulations
- MC-HMC method for computation of FIM enables applications to design optimization for discrete data but is computationally challenging (much slower than FO approach)

Perspectives

- Replacement of MC by more efficient approach: quasi-random sampling¹
- Accounting for model and parameter uncertainty^{2,3}
- Model based adaptive design^{4,5}
 - model averaging⁶



1: Ueckert S. *et al.*, CM Statistics Conference, UK, 2015

2: Foo LK. *et al.*, J Biopharm Stat, 2012

3: Loingeville F. *et al.*, PAGE meeting, 2017

4: Lestini G. *et al.*, Pharm Res., 2015

5: Strömberg EA. *et al.*, J Pharmacokinetics Pharmacodyn, 2017


6: Buckland ST. *et al.*, Biometrics, 1997

Thanks to


- You for listening
- The organizing committee
- IAME

Backup

α_m choice



Heatmaps



Predicted Power Wald test for N=100

Protocole \ Modèle final	M1 Linéaire	M2 Loglinéaire	M3 Quadratique	M4 Exp	AVERAGE
$\xi_{D,1}=(0,2,11,12)$	69.7%	58.0%	36.9%	35.4%	50.0%
$\xi_{D,2}=(0,1,8,12)$	58.0%	66.7%	47.5%	20.3%	48.1%
$\xi_{D,3}=(0,4,5,12)$	60.0%	50.6%	56.3%	8.7%	43.9%
$\xi_{D,4}=(0,6,11,12)$	54.6%	45.0%	67.6%	38.1%	51.3%
$\xi_{Ds,1}=(0,2,11,12)$	69.7%	58.0%	36.9%	35.4%	50.0%
$\xi_{Ds,2}=(0,1,11,12)$	57.4%	67.3%	33.6%	35.8%	48.5%
$\xi_{Ds,3}=(0,5,11,12)$	58.6%	46.3%	69.3%	37.7%	53.0%
$\xi_{Ds,4}=(0,10,11,12)$	43.6%	41.1%	48.6%	52.2%	46.4%
$\xi_{DDs,1}=(0,2,11,12)$	69.7%	58.0%	36.9%	35.4%	50.0%
$\xi_{DDs,2}=(0,1,11,12)$	57.4%	67.3%	33.6%	35.8%	48.5%
$\xi_{DDs,3}=(0,5,11,12)$	58.6%	46.3%	69.3%	37.7%	53.0%
$\xi_{DDs,4}=(0,9,11,12)$	45.6%	41.7%	52.6%	47.8%	46.9%
$\xi_{CD}=(0,5,11,12)$	58.6%	46.3%	69.3%	37.7%	53.0%
$\xi_{CDs}=(0,4,11,12)$	63.4%	48.5%	65.0%	37.1%	53.5%
$\xi_{CDDs}=(0,4,11,12)$	63.4%	48.5%	65.0%	37.1%	53.5%
$\xi_{ES}=(0,4,8,12)$	62.2%	49.0%	61.5%	24.4%	49.3%

Observed D-efficiencies

	M1	M2	M3	M4
$\xi_{\text{CDD}_S} : \text{reference}$	<i>1</i>	<i>1</i>	<i>1</i>	<i>1</i>
$\xi_{\text{DD}_S,1}$	1.11	1.06	0.79	0.74
ξ_{ES}	0.98	0.94	0.98	0.84

	M1	M2	M3	M4
FIM predicted power	0.968	0.889	0.973	0.77
CTS observed power	0.988	0.988	0.996	0.86
CTS observed power using simulated β	0.976	0.914	0.992	0.746